Neural tube defects in relation to use of folic acid antagonists during pregnancy

American Journal of Epidemiology

Volumn 153, Issue 10, 2001, Pages 961-968

  Hernández Díaz, Sonia ^a,b   Werler, Martha M ^a   Walker, Alexander M ^b   Mitchell, Allen A ^a  

^a BOSTON UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Carbamazepine; Case control studies; Folic acid antagonists; Neural tube defects; Pregnancy; Teratogens; Trimethoprim

Indexed keywords

CARBAMAZEPINE; FOLIC ACID ANTAGONIST; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SALAZOSULFAPYRIDINE; TRIAMTERENE; TRIMETHOPRIM;

ARTICLE; CANADA; CASE CONTROL STUDY; DRUG EXPOSURE; HUMAN; NEURAL TUBE DEFECT; PRENATAL EXPOSURE; RISK ASSESSMENT; TERATOGENICITY; UNITED STATES;

ADULT; CASE-CONTROL STUDIES; FEMALE; FOLIC ACID ANTAGONISTS; HUMANS; INCIDENCE; INFANT, NEWBORN; MALE; NEURAL TUBE DEFECTS; ODDS RATIO; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RISK FACTORS;

EID: 0035873403     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/153.10.961     Document Type: Article

References (31)

1. Conclusions
2. Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group
3. Drug and environmental factors associated with adverse pregnancy outcomes. Part II. Improvement with folic acid
4. Is disordered folate metabolism the basis for the genetic predisposition to neural tube defects?
5. Folate levels and neural tube defects. Implications for prevention
6. Therapeutic abortions with a folic acid antagonist, 4-aminopteroylglutamic acid (4-amino P.G.A.) administered by the oral route
7. Methotrexate-induced congenital malformations
8. Maternal use of antiepileptic drugs and the risk of major congenital malformations: A joint European prospective study of human teratogenesis associated with maternal epilepsy
9. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: A French prospective cohort study
10. Spina bifida in infants of women treated with carbamazepine during pregnancy
11. Birth defects related to Benedectin use in pregnancy
12. Special considerations in studies of drug-induced birth defects
13. Multivitamin supplementation and birth defect risks
14. Drug and environmental factors associated with adverse pregnancy outcomes. Part I. Antiepileptic drugs, contraceptives, smoking, and folate
15. Spina bifida and anencephaly: A problem in genetic-environmental interaction
16. Teratogens and craniofacial malformations: Relationships to cell death
17. Evaluation of anticonvulsant drugs during pregnancy in a population-based Hungarian study
18. The treatment of bacteriuria in pregnant women with sulphamethoxazole and trimethoprim
19. Trimethoprim-sulfamethoxazole in the treatment of bacteriuria in women
20. Single-dose antibacterial treatment for bacteriuria in pregnancy
21. Maternal drug histories and congenital malformations: Limb reduction defects and oral clefts
22. A case-control analysis of the teratogenic effects of co-trimoxazole
23. Antiepileptic drugs and teratogenesis in two consecutive cohorts: Changes in prescription policy paralleled by changes in pattern of malformations
24. Orofacial clefts and maternal anticonvulsant use
25. Folic acid metabolism in health and disease
26. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis
27. The role of folic acid in oral clefting
28. Alteration of embryonic folate metabolism by valproic acid during organogenesis: Implications for mechanism of teratogenesis
29. Toxicology of sulphonamide-trimethoprim combinations
30. Periconceptional folic acid exposure and risk of occurrent neural tube defects